Modulight Biotherapeutics is pioneering a new era of medicine for people living with neurological disorders- one that is fast-acting, precise, and designed to provide real relief without side effects. The Company's platform uses a unique approach for modulating neuronal activity using light-activated proteins that are specifically targeted to pathological cells and neural pathways. Modulight's therapeutic platform is based on technology licensed from YEDA, the commercial arm of the Weizmann Institute of Science.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/12/25 | $12,000,000 | Seed |
Fresh Fund Jibe Ventures  Localglobe Nexus NeuroTech Ventures RedSeed Saras Capital Secret Chord Ventures Sha'ar Mivnim SilverArc Capital | undisclosed |
